Eli Lilly reported first-quarter earnings and revenue that exceeded Wall Street expectations on Thursday and raised its full-year sales outlook by $2 billion, driven by strong demand for its obesity and diabetes treatments Zepbound and Mounjaro.
Eli Lilly is looking to position India as a key hub in its global supply chain as sales of its blockbuster weight-loss drug Mounjaro surge in the country.
U.S. pharmaceutical giant Eli Lilly’s weight-loss therapy Mounjaro has become India’s best-selling drug by value in October, surpassing GSK’s antibiotic Augmentin, according to new data from research firm Pharmarack.
30 Apr 2026-15:51
17 Feb 2026-14:20
